Aurora Spine Surpasses Milestone of 2,500 Procedures Using SiLO™ SI Joint Fusion System

CARLSBAD, CALIFORNIA, June 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a pioneer in innovative spinal solutions, proudly announces that its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System has been successfully used in over 2,500 procedures across the United States. This major milestone underscores the company’s accelerating growth and increasing adoption of its minimally invasive technology by surgeons nationwide.

Aurora’s SiLO™ platform, which includes the SiLO-TFX™ system, is engineered to improve outcomes for patients suffering from SI joint pain and dysfunction. Utilizing a posterior approach, the system enables secure transfixation across the SI joint, delivering enhanced fixation, reduced recovery times, and consistently high patient satisfaction.

“This milestone is a key indicator of market acceptance and commercial scalability,” said Trent Northcutt, CEO of Aurora Spine. “SiLO™ is resonating with surgeons who want smarter solutions, and this is only the beginning. Our commitment to innovation, education, and execution continues to unlock meaningful growth opportunities.”

Key Drivers of Growth:

• 2,500+ SiLO™ Procedures Performed Nationwide

• Rapid expansion of Aurora’s U.S. sales network

• Launch of targeted surgeon education programs

• Continued innovation across the minimally invasive spine portfolio

The SiLO-TFX™ system has gained traction due to its intuitive instrumentation and reproducible outcomes, as reflected in glowing feedback from the surgical community:

“The SiLO-TFX™ system offers unprecedented clinical advantages in my practice,” said Dr. Michael Stoffman, MD, Neurosurgeon. “The instrumentation is intuitive, precise, and designed with the surgeon’s workflow in mind, allowing for consistent, reproducible outcomes and improved patient recovery.”

In addition to the SiLO™ platform, Aurora’s growing suite of innovations includes the AERO™ Facet Fusion System and the DEXA TECHNOLOGY™-matched interbody implants—the world’s first spinal implants customized to a patient’s bone density.

“Our goal is to provide the most effective and least invasive treatment options, supported by robust clinical evidence,” said Matthew Goldstone, Chief Commercial Officer. “We’re proud to have multiple peer-reviewed publications in 2025, with more on the horizon. Clinical data is the key to shaping the future of spine care.”

“Aurora Spine leads in spine innovation with our SiLO™ platform, which has now surpassed 2,500 procedures,” added Laszlo Garamszegi, Chief Technology Officer. “Positive feedback from surgeons and patients continues to inspire us as we introduce advanced technologies like AERO™ and DEXA-based implants. We're committed to driving the future of minimally invasive spine treatments through design excellence and clinical science.”

Aurora Spine remains focused on delivering groundbreaking spinal technologies that empower surgeons, improve patient outcomes, and lead the evolution of minimally invasive spine surgery.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at -spine.com or Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Company Contacts: Aurora Spine Corporation 

Trent Northcutt 

‎President and Chief Executive Officer 

‎(760) 424-2004 

Chad Clouse 

‎Chief Financial Officer 

‎(760) 424-2004

‎

Investor Contact:

Adam Lowensteiner 

‎‎Lytham Partners 

‎‎(646) 829-9702

Email: